Since sTILs were detected only in 15 samples (30%), at a lower than expected rate for HR+/HER2– tumors, we did not perform a subpopulation analysis of immune components but just investigated the association of sTILs’ presence in tumor tissue and patient outcome and with clinical and other pathological features. The gene discussed is ERBB2; the disease is neoplasm.